Biogen (BIIB) Tops Q1 EPS by 62c; cuts EPS guidance
Biogen (NASDAQ: BIIB) reported Q1 EPS of $3.57, $0.62 better than the analyst estimate of $2.95. Revenue for the quarter came in at $2.48 billion versus the consensus estimate of $2.25 billion.
GUIDANCE:
Biogen sees FY2026 EPS of $14.25-$15.25, versus the consensus of $15.55. Year revenue expected to decline by a mid-single digit percentage as compared to 2025 as further declines in multiple sclerosis product revenue, excluding VUMERITY, are expected to be partially offset by increases in revenue from growth products
For earnings history and earnings-related data on Biogen (BIIB) click here.